GW Pharma Plans More Clinical Trials for Sativex

GW Pharma Plans More Clinical Trials for Sativex

282719

GW Pharma Plans More Clinical Trials for Sativex

GW Pharmaceuticals is planning to continue recruiting patients into two pivotal Phase 3 clinical trials of Sativex (nabiximols), an oral spray that contains cannabis extracts and is being investigated as a potential add-on therapy for people with multiple sclerosis (MS) and spasticity. The company also is planning to launch three additional clinical trials in the U.S. focused on exploring Sativex’s therapeutic potential for the treatment of spasticity (muscle stiffness or spasms) associated with MS. GW Pharmaceuticals anticipates…

You must be logged in to read/download the full post.